Vincerx Pharma, Inc. operates as a clinical-stage biopharmaceutical company which develops antibody drugs. The company is headquartered in Palo Alto, California and currently employs 12 full-time employees. The company went IPO on 2020-03-10. The firm is focused on developing differentiated and novel therapies to address the unmet medical needs of patients with cancer. The company has a next generation bioconjugation platform, called VersAptx. Its product candidates include VIP943 (CD123-KSPi), VIP924 (CXCR5-KSPi), VIP236, and Enitociclib (positive transcription elongation factor beta (P-TEFb)/CDK9 inhibitor). Its VIP943 is developed using its VersAptx platform and combines an anti-CD123 antibody, a novel legumain-cleavable linker and a kinesin spindle protein inhibitor payload enhanced with CellTrapper technology. Enitociclib is a selective CDK9 inhibitor. Enitociclib effectively blocks P-TEFb-mediated activation of RNA polymerase II, preventing transcription of MCL1 and MYC, proteins associated with poor prognosis in various types of cancer.
Follow-Up Questions
What is the price performance of VINC stock?
The current price of VINC is $0.04, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Vincerx Pharma Inc?
Vincerx Pharma Inc belongs to Biotechnology industry and the sector is Health Care
What is Vincerx Pharma Inc market cap?
Vincerx Pharma Inc's current market cap is $209.2K
Is Vincerx Pharma Inc a buy, sell, or hold?
According to wall street analysts, 3 analysts have made analyst ratings for Vincerx Pharma Inc, including 2 strong buy, 4 buy, 1 hold, 0 sell, and 2 strong sell
